<DOC>
	<DOCNO>NCT02075255</DOCNO>
	<brief_summary>The purpose trial confirm benralizumab reduce use maintenance OCS systemic corticosteroid dependent patient severe refractory asthma elevate eosinophil .</brief_summary>
	<brief_title>Efficacy Safety Study Benralizumab Reduce OCS Use Patients With Uncontrolled Asthma High Dose Inhaled Corticosteroid Plus LABA Chronic OCS Therapy</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>1 . Provision inform consent prior study specific procedure . 2 . Female male age 18 75 year , inclusively . 3 . History physiciandiagnosed asthma require treatment medium dose ICS LABA . 4 . Elevated level peripheral blood eosinophil 5 . Documented treatment highdose ICS LABA least 6 month prior Visit 1 6 . Chronic oral corticosteroid therapy least 6 continuous month directly precede Visit 1 . Subjects must dose equivalent 7.5 40 mg/day prednisolone/prednisone Visit 1 stable dose least 2 week prior randomization . Patients must agree switch study require prednisone/prednisolone oral corticosteroid duration study . 7 . Patients document failure OCS reduction within 6 month prior Visit 1 require proceed dose optimization phase runin . 8 . Morning prebronchodilator ( PreBD ) FEV1 &lt; 80 % predict 9 . Evidence asthma document either : Airway reversibility ( FEV1 ≥12 % 200 mL ) demonstrate Visit 1 , Visit 2 , Visit 3 use Maximum Postbronchodilator Procedure OR Documented reversibility previous 24 month prior Visit 1 OR Airway hyperresponsiveness ( PC20 FEV1 methacholine concentration ≤8mg/mL ) document previous 12 month prior plan date randomization OR Airflow variability clinic FEV1 ≥20 % 2 consecutive clinic visit document 12 month prior plan date randomization ( FEV1 record exacerbation consider criterion ) . All patient must reversibility test perform randomization establish baseline characteristic . If patient demonstrate airway reversibility either Visit 1 Visit 2 need qualify patient randomization , site reiterate need withhold short longacting bronchodilator prior Visit 3 effort meet inclusion criterion . 10 . At least 1 documented asthma exacerbation previous 12 month prior date informed consent obtain 11 . Optimized OCS dose reach least 2 week prior randomization 12 . Additional asthma controller medication must initiate run in/optimization period ( applicable management exacerbation screening/ run optimization phase ) 13 . At least 70 % compliance OCS use 14 . At least 70 % compliance usual asthma controller ICSLABA 15 . Minimum 70 % ( i.e . 10 14 day ) compliance asthma daily diary ( morning even diary ) Exclusion criterion : 1 . Clinically important pulmonary disease asthma ever diagnose pulmonary systemic disease , asthma , associate elevated peripheral eosinophil count . 2 . Any disorder , include , limited , cardiovascular , gastrointestinal , hepatic , renal , neurological , musculoskeletal , infectious , endocrine , metabolic , hematological , psychiatric , major physical impairment stable opinion Investigator could : Affect safety patient throughout study Influence finding study interpretation Impede patient 's ability complete entire duration study 3 . Acute upper low respiratory infection require antibiotic antiviral medication within 30 day prior date informed consent obtain screening/runin period 4 . Any clinically significant abnormal finding physical examination , vital sign , hematology , clinical chemistry , urinalysis runin/optimization period , opinion Investigator , may put patient risk his/her participation study , may influence result study , patient 's ability complete entire duration study 5 . History lifethreatening asthma 6 . Asthma control reach OCS dose ≤5mg runin/OCS optimization phase 7 . Qualifies 3 consecutive dose reduction Visits 24 continue meet OCS dose reduction criterion Visit 5 8 . Receipt oral corticosteroid , prednisone prednisolone , maintenance oral steroid controller asthma symptom Visit 1 throughout study . 9 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) level ≥2.5 time upper limit normal ( ULN ) confirm screening period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Asthma , Bronchial Diseases , Respiratory Tract Diseases , Lung Diseases , Obstructive Lung Diseases , OCS , Oral Corticosteroids</keyword>
</DOC>